ClinicalTrials.gg

Program

engasertib

Also written as “Engasertib” and “VAD044 Part II”.

Its studies are mostly in Telangiectasia, Hereditary Hemorrhagic, led by Vaderis Therapeutics.

Furthest: phase 3, since Jul 29, 20264 company-led studies, 3 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vaderis Therapeutics43 open or runningphase 3since Jul 29, 2026May 10, 2022Jan 2027phase 2 · NCT05406362

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 10, 2022First study: phase 2 study in Telangiectasia, Hereditary HemorrhagicFirst studyNCT05406362 · 75 enrolled · United States, Belgium, France and more
  2. Jul 29, 2026Phase 3 study in Telangiectasia, Hereditary HemorrhagicPhase 3 reachedNCT07743671 · 240 planned · United States, Belgium, France and more
  3. Aug 28, 2026Phase 1 study in Healthy ParticipantsNCT07800429 · 27 enrolled · Germany
  4. Nov 9, 2026Phase 1 study in Hepatic ImpairmentNCT07939867 · 18 planned

Ahead

  1. Jan 2027Primary completion: phase 2 study in Telangiectasia, Hereditary HemorrhagicNCT05406362
  2. Apr 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07939867
  3. Jun 2028Primary completion: phase 3 study in Telangiectasia, Hereditary HemorrhagicNCT07743671

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07939867Hepatic Impairment1Not yet recruitingApr 202718
NCT07800429Healthy Participants · Germany1CompletedOct 28, 202627
NCT07743671Telangiectasia, Hereditary Hemorrhagic · United States, Belgium, France and more3RecruitingJun 2028240
NCT05406362Telangiectasia, Hereditary Hemorrhagic · United States, Belgium, France and more2Active, not recruitingJan 202775

How it is read

Names in the registry

  • “Engasertib”, 3 entries
  • “VAD044 Part II”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.